Sinovac Biotech Ltd.’s coronavirus shot created antibodies among 97% of those administered with the shot in a final stage trial in Indonesia but its efficacy has yet to be determined, a company spokesperson said Tuesday.The clarification came after Sinovac’s Indonesian partner, PT Bio Farma, said that the vaccine had proven 97% effective in early clinical trials there.
When asked about Sinovac’s response, Bio Farma refrained from agreeing and instead said the final efficacy rate will only be concluded in January.Sinovac said that the 97% figure referred to the seroconversion rate, which is separate from the vaccine’s efficacy, as a high seroconversion rate does not necessarily mean that the vaccine effectively protects people against.